Literature DB >> 21796655

Development of a castrate resistant transplant tumor model of prostate cancer.

Leigh Ellis1, Kristin Lehet, Swathi Ramakrishnan, Remi Adelaiye, Roberto Pili.   

Abstract

BACKGROUND: Currently, limited mouse models that mimic the clinical course of castrate resistant prostate development currently exist. Such mouse models are urgently required to conduct pre-clinical studies to assist in the understanding of disease progression and the development of rational therapeutic strategies to treat castrate resistant prostate cancer.
METHODS: Wild type intact FVB male mice were injected by subcutaneous injection with Myc-CaP cells to establish androgen sensitive Myc-CaP tumors. Tumor bearing mice were castrated and resulting tumors serially passaged in pre-castrated FVB male mice to produce a bone fide Myc-CaP castrate resistant tumor.
RESULTS: Immunohistochemical analysis revealed that initial androgen sensitive Myc-CaP tumors had strong nuclear transcriptional active androgen receptor expression, as indicated by marked c-MYC staining and were highly proliferative. Castration of tumor bearing animals resulted in cytoplasmic relocation of androgen receptor concurrent with loss of transcriptional activity and tumor proliferation. Serial passaging of castrate refractory Myc-CaP in pre-castrated male FVB mice resulted in the development of a bona fide castrate resistant Myc-CaP tumor which pheno-copied the original androgen sensitive parental Myc-CaP tumor.
CONCLUSIONS: Developing a murine castrate transplant resistant tumor model that mimics the clinical course of human castrate resistant prostate cancer will create better opportunities to understand the development of castrate resistant prostate cancer and also allow for more rapid pre-clinical studies to stratify rational novel therapies for this lethal form of prostate cancer.
Copyright © 2011 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21796655      PMCID: PMC3298731          DOI: 10.1002/pros.21465

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  11 in total

Review 1.  Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis.

Authors:  Howard I Scher; Charles L Sawyers
Journal:  J Clin Oncol       Date:  2005-11-10       Impact factor: 44.544

2.  Context-dependent hormone-refractory progression revealed through characterization of a novel murine prostate cancer cell line.

Authors:  Philip A Watson; Katharine Ellwood-Yen; Jennifer C King; John Wongvipat; Michelle M Lebeau; Charles L Sawyers
Journal:  Cancer Res       Date:  2005-12-15       Impact factor: 12.701

3.  Mouse prostate cancer cell lines established from primary and postcastration recurrent tumors.

Authors:  Chun-Peng Liao; Mengmeng Liang; Michael B Cohen; Andrea Flesken-Nikitin; Joseph H Jeong; Alexander Yu Nikitin; Pradip Roy-Burman
Journal:  Horm Cancer       Date:  2010-02       Impact factor: 3.869

4.  Development of a second-generation antiandrogen for treatment of advanced prostate cancer.

Authors:  Chris Tran; Samedy Ouk; Nicola J Clegg; Yu Chen; Philip A Watson; Vivek Arora; John Wongvipat; Peter M Smith-Jones; Dongwon Yoo; Andrew Kwon; Teresa Wasielewska; Derek Welsbie; Charlie Degui Chen; Celestia S Higano; Tomasz M Beer; David T Hung; Howard I Scher; Michael E Jung; Charles L Sawyers
Journal:  Science       Date:  2009-04-09       Impact factor: 47.728

5.  The histone deacetylase inhibitors LAQ824 and LBH589 do not require death receptor signaling or a functional apoptosome to mediate tumor cell death or therapeutic efficacy.

Authors:  Leigh Ellis; Michael Bots; Ralph K Lindemann; Jessica E Bolden; Andrea Newbold; Leonie A Cluse; Clare L Scott; Andreas Strasser; Peter Atadja; Scott W Lowe; Ricky W Johnstone
Journal:  Blood       Date:  2009-04-21       Impact factor: 22.113

6.  The current state of preclinical prostate cancer animal models.

Authors:  Kenneth J Pienta; Cory Abate-Shen; David B Agus; Ricardo M Attar; Leland W K Chung; Norman M Greenberg; William C Hahn; John T Isaacs; Nora M Navone; Donna M Peehl; Jonathon W Simons; David B Solit; Howard R Soule; Terry A VanDyke; Michael J Weber; Lily Wu; Robert L Vessella
Journal:  Prostate       Date:  2008-05-01       Impact factor: 4.104

7.  Murine cell lines derived from Pten null prostate cancer show the critical role of PTEN in hormone refractory prostate cancer development.

Authors:  Jing Jiao; Shunyou Wang; Rong Qiao; Igor Vivanco; Philip A Watson; Charles L Sawyers; Hong Wu
Journal:  Cancer Res       Date:  2007-07-01       Impact factor: 12.701

8.  Molecular determinants of resistance to antiandrogen therapy.

Authors:  Charlie D Chen; Derek S Welsbie; Chris Tran; Sung Hee Baek; Randy Chen; Robert Vessella; Michael G Rosenfeld; Charles L Sawyers
Journal:  Nat Med       Date:  2003-12-21       Impact factor: 53.440

9.  Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer.

Authors:  Shunyou Wang; Jing Gao; Qunying Lei; Nora Rozengurt; Colin Pritchard; Jing Jiao; George V Thomas; Gang Li; Pradip Roy-Burman; Peter S Nelson; Xin Liu; Hong Wu
Journal:  Cancer Cell       Date:  2003-09       Impact factor: 31.743

10.  Myc-driven murine prostate cancer shares molecular features with human prostate tumors.

Authors:  Katharine Ellwood-Yen; Thomas G Graeber; John Wongvipat; M Luisa Iruela-Arispe; JianFeng Zhang; Robert Matusik; George V Thomas; Charles L Sawyers
Journal:  Cancer Cell       Date:  2003-09       Impact factor: 31.743

View more
  14 in total

1.  Androgen-Regulated SPARCL1 in the Tumor Microenvironment Inhibits Metastatic Progression.

Authors:  Paula J Hurley; Robert M Hughes; Brian W Simons; Jessie Huang; Rebecca M Miller; Brian Shinder; Michael C Haffner; David Esopi; Yasunori Kimura; Javaneh Jabbari; Ashley E Ross; Nicholas Erho; Ismael A Vergara; Sheila F Faraj; Elai Davicioni; George J Netto; Srinivasan Yegnasubramanian; Steven S An; Edward M Schaeffer
Journal:  Cancer Res       Date:  2015-08-20       Impact factor: 12.701

2.  Tasquinimod modulates suppressive myeloid cells and enhances cancer immunotherapies in murine models.

Authors:  Li Shen; Anette Sundstedt; Michael Ciesielski; Kiersten Marie Miles; Mona Celander; Remi Adelaiye; Ashley Orillion; Eric Ciamporcero; Swathi Ramakrishnan; Leigh Ellis; Robert Fenstermaker; Scott I Abrams; Helena Eriksson; Tomas Leanderson; Anders Olsson; Roberto Pili
Journal:  Cancer Immunol Res       Date:  2014-11-04       Impact factor: 11.151

3.  Prostate Cancer Cells Express More Androgen Receptor (AR) Following Androgen Deprivation, Improving Recognition by AR-Specific T Cells.

Authors:  Brian M Olson; Melissa Gamat; Joseph Seliski; Thomas Sawicki; Justin Jeffery; Leigh Ellis; Charles G Drake; Jamey Weichert; Douglas G McNeel
Journal:  Cancer Immunol Res       Date:  2017-10-19       Impact factor: 11.151

4.  Radium-223 Treatment Increases Immune Checkpoint Expression in Extracellular Vesicles from the Metastatic Prostate Cancer Bone Microenvironment.

Authors:  Ioulia Vardaki; Paul Corn; Emanuela Gentile; Jian H Song; Namrata Madan; Anh Hoang; Nila Parikh; Leah Guerra; Yu-Chen Lee; Song-Chang Lin; Guoyu Yu; Elmer Santos; Marites P Melancon; Patricia Troncoso; Nora Navone; Gary E Gallick; Eleni Efstathiou; Sumit K Subudhi; Sue-Hwa Lin; Christopher J Logothetis; Theocharis Panaretakis
Journal:  Clin Cancer Res       Date:  2021-03-22       Impact factor: 12.531

5.  Concurrent HDAC and mTORC1 inhibition attenuate androgen receptor and hypoxia signaling associated with alterations in microRNA expression.

Authors:  Leigh Ellis; Kristin Lehet; Swathi Ramakrishnan; Remi Adelaiye; Kiersten M Miles; Dan Wang; Song Liu; Peter Atadja; Michael A Carducci; Roberto Pili
Journal:  PLoS One       Date:  2011-11-07       Impact factor: 3.240

6.  Class I histone deacetylase inhibitor entinostat suppresses regulatory T cells and enhances immunotherapies in renal and prostate cancer models.

Authors:  Li Shen; Michael Ciesielski; Swathi Ramakrishnan; Kiersten M Miles; Leigh Ellis; Paula Sotomayor; Protul Shrikant; Robert Fenstermaker; Roberto Pili
Journal:  PLoS One       Date:  2012-01-27       Impact factor: 3.240

7.  A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer.

Authors:  Jonathan F Anker; Hanlin Mok; Anum F Naseem; Praveen Thumbikat; Sarki A Abdulkadir
Journal:  J Vis Exp       Date:  2018-03-06       Impact factor: 1.355

8.  Inhibition of Hsp90 augments docetaxel therapy in castrate resistant prostate cancer.

Authors:  ShengYu Ku; Elena Lasorsa; Remi Adelaiye; Swathi Ramakrishnan; Leigh Ellis; Roberto Pili
Journal:  PLoS One       Date:  2014-07-29       Impact factor: 3.240

9.  Generation of a syngeneic orthotopic transplant model of prostate cancer metastasis.

Authors:  Leigh Ellis; Kristin Lehet; ShengYu Ku; Gissou Azabdaftari; Roberto Pili
Journal:  Oncoscience       Date:  2014-10-15

10.  Interleukin-17 Indirectly Promotes M2 Macrophage Differentiation through Stimulation of COX-2/PGE2 Pathway in the Cancer Cells.

Authors:  Qingli Li; Lunxu Liu; Qiuyang Zhang; Sen Liu; Dongxia Ge; Zongbing You
Journal:  Cancer Res Treat       Date:  2014-07-15       Impact factor: 4.679

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.